RxDoctor Payments Data

Beverly Drucker, MD

Medical Oncology · Greenwich, CTNPI 1104834704

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,858 of the $11,978 with a category attached, or 82.3%. 14 manufacturers reported payments, led by EMD Serono, Inc. at 40.0% of the total. Reporting peaked in 2019 at $5,647 and has fallen 84.8% since, to $859 in 2024.

$11,978in general payments, 2019–2025

Across 25 payments — averaging $479.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$5K
  • GSK$2K
  • Genentech USA, Inc.$2K
  • Astellas Pharma Global Development$2K
  • AstraZeneca$525
  • Stemline Therapeutics Inc.$250
  • plus $927 from 8 others
$11,475in research payments, 2019–2025

Across 2 payments — averaging $5737.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$11K

What the payments were for

  • Consulting fees$9,85882%
  • Travel & lodging$6355%
  • Food & beverage$1,38912%
  • Education$961%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,978 in reported general payments places this provider in the 60th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$132,560
Medicare patients
441
Services billed
1,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib41$592,844
IbrancePalbociclib24$385,513
TagrissoOsimertinib Mesylate12$203,874
ImbruvicaIbrutinib12$196,347
MekinistTrametinib Dimethyl Sulfoxide11$154,125
Abiraterone Acetate23$94,085
Everolimus12$28,057
EliquisApixaban35$27,826
Exemestane49$8,524
Anastrozole242$5,326
Letrozole92$2,663
Raloxifene Hcl59$2,607
Tamoxifen Citrate52$1,048
Oxycodone Hcl26$567
Furosemide47$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$84$413,33959 claims
AstraZenecaTagrisso$525$203,87412 claims
NovartisMekinist$125$154,12511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 79 medical oncology providers in Connecticut.

Other medical oncology in Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →